Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 27, 2026

FlightPath Golf Tees Get Reviewed for Effective Accuracy and Distance - Results Inside

View original at globenewswire.com
FlightPath Golf Tees Get Reviewed for Effective Accuracy and Distance - Results Inside Altamonte Springs, FL, March 26, 2026 (GLOBE NEWSWIRE) -- FlightPath Golf conducts ongoing product evaluation and performance analysis as part of its development process…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No swing changes are required to use FlightPath tees; the setup process is slightly different but becomes natural after a short adjustment period

    60% confidence
  • Each FlightPath tee is designed to last over 100 rounds due to impact-resistant polycarbonate construction

    60% confidence
  • The angled launch platform design reduces backspin on drives, which may translate to more carry distance without requiring swing modifications

    60% confidence
  • FlightPath tees are manufactured in Cocoa Beach, Florida and are 100% made and patented in the USA

    60% confidence
  • FlightPath tees have been reviewed by the USGA and issued an official conformance letter, making them legal for tournament use under USGA and R&A rules

    60% confidence
  • The diamond-patterned contact surface reduces friction in the direction of the swing, which may promote more consistent ball flight

    60% confidence
  • Traditional wooden tees break approximately every three holes according to Golf Magazine survey

    60% confidence
  • Third-party robotic testing demonstrated measurable differences in distance and precision

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com